It could be that, or it could partly be because I keep hassling...

It could be that, or it could partly be because I keep hassling Adam about the lack of details on what is happening in China ... based on the SPS sales announced thus far, there is still a huge gap between US$5.6m and US$26m ... even more so when the target was US44m ... hopefully Adam has listend to me (and others I'm sure) who are asking for more colour when it comes to quarteries.

I think the fact that management have flagged a huge Q4 in terms of revenue, and more importantly multi-year Aspiral sales to new Chinese provinces ... the share price won't fall much further.. because if it does, it will surely be snapped up quickly ... two months is a blink of an eye when it comes to investment returns ... while US$26m is the FY19 target, the real win is the on-going revenue that these deals are going to contribute to the business, and more importantly it will emphatically announce the acceptance of MABR as the best in class water treatment module in China ... analysts will have a field day extrapolating that for many years to come.